Unveiling Details, Unlocking Hope
Comprehensive Genomic & Transcriptomic Profiling with
High-sensitive ctDNA-MRD Monitoring
DNA
Genomic profiling of 515 genes in tumor tissue and 113 - 149 genes in liquid biopsy (panel depends on cancer type)
RNA
Transcriptomic profiling (mRNA‑seq) of 19.435 genes
ctDNA-MRD
LOD: 0.005%
Up to 50 personalized mutations
Viral DNA (HPV, EBV, HBV)
Genome-wide features with AI-enhanced
TAT: 8 days
Comprehensive report with fast turn‑around time
Informed Decision-making with Comprehensive Tumor-Liquid Biopsy Profiling
K-4CARE integrates cutting-edge genomic and transcriptomic profiling with AI-enhanced ctDNA-MRD monitoring, empowering clinicians to deliver personalized cancer care. Our platform aligns with guidelines from leading organizations, including: the National Comprehensive Cancer Network (NCCN), European Society for Medical Oncology (ESMO), and U.S. Food and Drug Administration (FDA).
By integrating DNA, RNA, and ctDNA insights, K-4CARE delivers:- Comprehensive biomarker coverage for diagnosis, prognosis, and therapy selection.
- Enhanced detection of rare structural variants and fusion events.
- Boosts detection sensitivity by 20% for both common and rare fusion variants. (1)
- High accuracy (up to 87.7%) for predicting cancer Tissue of Origin (TOO) in Cancer of Unknow Primary (CUP) using a proprietary machine‑learning model. (1)
This approach provides a comprehensive molecular landscape of the tumor, facilitating informed clinical decision-making and ultimately improving patient outcomes.
(1) Tran NHB, et al. Tumor genomic and transcriptomic analysis integrated with liquid biopsy CTDNA monitoring: analytical validation and clinical insights. Cancer Medicine. 2025;14(23):e71465.
High‑Sensitivity ctDNA‑MRD Monitoring
at 0.005% LOD track treatment response and detect recurrence early with real‑time variant monitoring for emerging resistance and new therapeutic opportunities.
K‑4CARE provides high‑sensitivity ctDNA‑MRD monitoring to track each patient’s personalized molecular profile, including:
- Personalized monitoring of up to 50 mutations
- Cancer-specific panels (Thoracic 125; Digestive 113; Breast & Gynecological 149) report SNVs/indels, amplifications, fusions
- Viral DNA (HPV, EBV, HBV)
- Genome-wide features (CNA, fragmentomics) with AI-enhanced
K‑4CARE also offers a no‑cost ctDNA baseline result, followed by cost‑effective ctDNA‑MRD follow‑up testing (K‑4CARE n) that requires only a blood sample and is fully tailored to each patient’s unique tumor profile.
Benefit of Comprehensive Genomic-Transcriptomic Profiling
1. Actionable and Resistance Mutations
Identify genetic alterations to guide targeted therapy (FDA-approved or investigated in clinical trials) for pan-cancer
2. MSI, TMB, PD-L1*
Predictive biomarkers of tumor response to immune-checkpoint inhibitors for pan-cancer
3. Homologous Recombination Deficiency (HRD)
Predictive biomarker of tumor response to PARP inhibitors and platinum-based chemotherapy for selected cancers
4. Germline Mutations (Pharmacogenomics and Hereditery cacner risk)
Identify inherited cancer predispositions and guide personalized therapy for selected cancers. Detect DPYD pharmacogenomic variants to enable safer use of fluoropyrimidines.
5. Tumor Tissue of Origin for CUP
Identify the tumor tissue of origin for Cancer of Unknown Primary (CUP) to enable site-specific therapy
6. Oncovirus Profile (Viral DNA)
Detect viral DNA (HPV, EBV, HBV) linked to selected cancers, which can influence diagnosis, prognosis, and treatment choices
Why K-4CARE
Sequence Both DNA (515 genes + sWGS) + mRNA (19,435 genes)
Integrated Profiling: Tissue and Liquid Biopsies
All‑in‑One Testing Delivered in Just 8 Days
Integrated ctDNA-MRD Monitoring
Sample collection
Tissue FFPE Sample
The tumor cellularity
must be ≥30%
